Cargando…

The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance

Radiation therapy is an important tool for malignant tumors, and its tolerance needs to be addressed. In recent years, several studies have shown that regulators of aberrant m6A methylation play an important role in the formation, development and invasion and metastasis of tumors. A large number of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yi, Gu, Wendong, Shao, Yingjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390431/
https://www.ncbi.nlm.nih.gov/pubmed/37522921
http://dx.doi.org/10.1007/s12672-023-00759-3
_version_ 1785082474075783168
author Zhang, Yi
Gu, Wendong
Shao, Yingjie
author_facet Zhang, Yi
Gu, Wendong
Shao, Yingjie
author_sort Zhang, Yi
collection PubMed
description Radiation therapy is an important tool for malignant tumors, and its tolerance needs to be addressed. In recent years, several studies have shown that regulators of aberrant m6A methylation play an important role in the formation, development and invasion and metastasis of tumors. A large number of studies have confirmed aberrant m6A methylation as a new target for tumour therapy, but research on whether it can play a role in tumor sensitivity to radiotherapy has not been extensive and thorough enough. Recent studies have shown that all three major enzymes of m6A methylation have significant roles in radioresistance, and that the enzymes that play a role differ in different tumor types and by different mechanisms, including regulating tumor cell stemness, affecting DNA damage and repair, and controlling the cell cycle. Therefore, elucidating the mechanisms of m6A methylation in the radiotherapy of malignant tumors is essential to counteract radioresistance, improve the efficacy of radiotherapy, and even propose targeted treatment plans for specific tumors. The latest research progress on m6A methylation and radioresistance is reviewed in this article.
format Online
Article
Text
id pubmed-10390431
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-103904312023-08-02 The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance Zhang, Yi Gu, Wendong Shao, Yingjie Discov Oncol Review Radiation therapy is an important tool for malignant tumors, and its tolerance needs to be addressed. In recent years, several studies have shown that regulators of aberrant m6A methylation play an important role in the formation, development and invasion and metastasis of tumors. A large number of studies have confirmed aberrant m6A methylation as a new target for tumour therapy, but research on whether it can play a role in tumor sensitivity to radiotherapy has not been extensive and thorough enough. Recent studies have shown that all three major enzymes of m6A methylation have significant roles in radioresistance, and that the enzymes that play a role differ in different tumor types and by different mechanisms, including regulating tumor cell stemness, affecting DNA damage and repair, and controlling the cell cycle. Therefore, elucidating the mechanisms of m6A methylation in the radiotherapy of malignant tumors is essential to counteract radioresistance, improve the efficacy of radiotherapy, and even propose targeted treatment plans for specific tumors. The latest research progress on m6A methylation and radioresistance is reviewed in this article. Springer US 2023-07-31 /pmc/articles/PMC10390431/ /pubmed/37522921 http://dx.doi.org/10.1007/s12672-023-00759-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Zhang, Yi
Gu, Wendong
Shao, Yingjie
The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance
title The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance
title_full The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance
title_fullStr The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance
title_full_unstemmed The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance
title_short The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance
title_sort therapeutic targets of n6-methyladenosine (m6a) modifications on tumor radioresistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390431/
https://www.ncbi.nlm.nih.gov/pubmed/37522921
http://dx.doi.org/10.1007/s12672-023-00759-3
work_keys_str_mv AT zhangyi thetherapeutictargetsofn6methyladenosinem6amodificationsontumorradioresistance
AT guwendong thetherapeutictargetsofn6methyladenosinem6amodificationsontumorradioresistance
AT shaoyingjie thetherapeutictargetsofn6methyladenosinem6amodificationsontumorradioresistance
AT zhangyi therapeutictargetsofn6methyladenosinem6amodificationsontumorradioresistance
AT guwendong therapeutictargetsofn6methyladenosinem6amodificationsontumorradioresistance
AT shaoyingjie therapeutictargetsofn6methyladenosinem6amodificationsontumorradioresistance